Health Care · Pharmaceutical Preparations

OLMA Olema Pharmaceuticals, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 175028488 filings
Russell 2000

OLMA at a glance

Olema Pharmaceuticals, Inc. (OLMA, SEC CIK 1750284) filed its latest 10-K annual report on March 16, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as September 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • As of September 30, 2026, 25 institutional investment managers tracked by SignalX reported holding Olema Pharmaceuticals, Inc. (OLMA) shares worth $238.8 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Harmon Cyrus on July 24, 2026 of 12,500 shares at $11.71 per share.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
25 funds
$238.8M · −1 vs prior quarter
Latest 8-K
Nov 12, 2026
Item 7.01 · Item 5.03 · Item 8.01

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business: Clinical-stage biopharma developing next-generation targeted therapies for ER+ breast cancer, emphasizing oral small molecule endocrine therapies
  • New emphasis: Initiated pivotal Phase 3 OPERA-01 trial for palazestrant monotherapy (2023) and Phase 3 OPERA-02 trial with ribociclib combination (2025)
  • Strategic shift: Collaboration with Novartis for ribociclib supply, advancing palazestrant as potential endocrine therapy of choice in frontline metastatic breast cancer
  • Quantitative highlight: Over 400 patients treated with palazestrant; FDA Fast Track designation granted in July 2022
  • Noteworthy: Second product OP-3136 entered clinical development in late 2024 targeting KAT6, with IND clearance and ongoing Phase 1 trial enrollment

Risk Factors

  • FDA regulatory risk: reliance on successful OPERA-01 Phase 3 trial results expected fall 2026 for NDA submission and potential FDA approval by late 2027
  • Geopolitical/macroeconomic threat: funding and operational risks tied to global economic uncertainty and volatile credit markets impacting capital raises and collaborations
  • Supply chain vulnerability: dependence on third-party contract manufacturers (CMOs) for clinical and potential commercial production with no in-house manufacturing
  • Competitive risk: Novartis collaboration supplying ribociclib for OPERA-02 trial, with palazestrant competing against established CDK4/6 inhibitors like palbociclib and ribociclib
  • Financial risk: accumulated deficit $597.6 million with net losses increasing to $162.5 million in 2025, requiring ongoing substantial capital raises including $237 million net from 2024 private placement

Management Discussion & Analysis

  • Revenue and profitability details not disclosed in the provided MD&A excerpt
  • Cash flow, capital allocation, buybacks, dividends, and capex information not included
  • Forward-looking statements indicating potential risks and uncertainties affecting actual results and events timing

AI summary of the OLMA 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • Newly triggered debt risk: Fourth Amendment added Olema Oncology International Limited as secured guarantor on July 1, 2026
  • Most material financial update: outstanding Credit Facility liability reached $3.0 million as of September 30, 2026
  • Regulatory risk: FDA may issue a Refusal to File if palazestrant NDA deficiencies preclude substantive review
  • Operational risk: OPERA-02 Phase 3 trial combines palazestrant with ribociclib, exposing development to combination-therapy dependencies
  • Competitive risk: palazestrant faces approved competitors including ORSERDU, ETCAMAH, and Inluriyo

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, no product sales
  • Net loss $73.6M vs $42.2M YoY, operating margin not disclosed
  • R&D largest expense $67.6M, up 69% YoY, driven by OPERA trials and OP-3136
  • Cash, equivalents and securities $413.8M; operating cash use $139.0M vs $108.4M
  • Runway through mid-2028; OPERA-01 results expected Q1 2027, funding and macroeconomic risks remain

AI summary of the OLMA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 12, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Olema Oncology announced a corporate name change on November 12, 2026
  • Name change may affect ticker, branding, investor communications and corporate records

Item 5.03: Amendments to Articles of Incorporation or Bylaws

  • Corporate name changed from Olema Pharmaceuticals, Inc. to Olema Oncology, Inc. effective November 12, 2026
  • Name change required no stockholder approval, reducing execution friction

Item 8.01: Other Events

  • Principal executive offices relocated effective November 12, 2026
  • New headquarters: 365 Oyster Point Blvd., Suite 400, South San Francisco, California

Item EX-99.1: Item EX-99.1

  • Corporate name changed to Olema Oncology, Inc. effective November 12, 2026
  • Nasdaq listing and ticker unchanged: OLMA on the Nasdaq Global Select Market
Filed Nov 10, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results for quarter ended September 30, 2026
  • Full results and management commentary available in Exhibit 99.1 press release

Item EX-99.1: Item EX-99.1

  • Q3 net loss widened to $73.6M from $42.2M, reflecting accelerated Phase 3 enrollment and commercialization preparation
  • Cash, equivalents and marketable securities declined to $413.8M from $505.4M at December 31, 2025
Filed Oct 15, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Dr. Gorjan Hrustanovic resigned from the Board effective October 14, 2026
  • Committee departures included Compensation and Science and Technology committees

AI summaries of OLMA 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for OLMA

Don't miss the next OLMA filing

  • Alerts as it files. A push when OLMA files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut OLMA, by share count.
  • Ask anything. An AI agent that reads every OLMA filing and answers with sources.

OLMA alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
O'Byrne JasonASep 1, 2026-
Harmon CyrusSellJul 24, 2026$11.71
Harmon CyrusSellJul 23, 2026$11.58
Harmon CyrusAJun 18, 2026-
BUTITTA CYNTHIA MAJun 18, 2026-
Horning SandraAJun 18, 2026-
CLARK IAN TAJun 18, 2026-
Larson YiAJun 18, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Operating Income-$105.0M-$142.3M-$178.7M
Net Income-$96.7M-$129.5M-$162.5M
Balance Sheet
Total Assets$276.9M$451.0M$533.4M
Equity$253.9M$409.0M$478.6M
ROE-38.1%-31.7%-33.9%
Per Share
EPS$-2.14$-2.20$-1.87
Cash Flow
Operating CF-$83.7M-$104.4M-$146.7M
CapEx-$159K-

Source: XBRL data in Olema Pharmaceuticals, Inc. (OLMA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate OLMA share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
OLMA shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202625$238.8M
Q2 202626$508.9M
Q1 202627$500.7M
Q4 202525$592.9M
Q3 202523$198.0M
Q2 202524$91.4M
Q1 202521$54.7M
Q4 202418$59.4M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 189 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

OLMA filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 12, 2026Analysis-
8-KNov 10, 2026Analysis-
10-QNov 10, 2026Analysis
8-KOct 15, 2026Analysis-
4Sep 2, 2026--
8-KAug 13, 2026Analysis-
10-QAug 10, 2026Analysis
8-KAug 10, 2026Analysis-
4Jul 27, 2026--
4Jun 23, 2026--
4Jun 23, 2026--
4Jun 23, 2026--
4Jun 23, 2026--
4Jun 23, 2026--
4Jun 23, 2026--
4Jun 23, 2026--
8-KJun 23, 2026Analysis-
4Jun 23, 2026--
4Jun 23, 2026--
4Jun 23, 2026--
4Jun 23, 2026--
8-KMay 26, 2026Analysis
8-KMay 21, 2026Analysis
8-KMay 12, 2026Analysis
10-QMay 12, 2026Analysis

Related Health Care companies

All Health Care →

OLMA SEC filings: frequently asked questions

Which institutions hold OLMA stock?

As of September 30, 2026, the largest Olema Pharmaceuticals, Inc. (OLMA) holders among the 13F filers tracked by SignalX were BlackRock ($62.0 million), State Street Corp ($33.2 million), Vanguard Capital Management LLC ($30.4 million), Morgan Stanley ($20.6 million), Franklin Resources ($17.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What are the main risks in OLMA's latest 10-K?

In the 10-K filed March 16, 2026, Olema Pharmaceuticals, Inc. (OLMA) flagged: FDA regulatory risk: reliance on successful OPERA-01 Phase 3 trial results expected fall 2026 for NDA submission and potential FDA approval by late 2027. Geopolitical/macroeconomic threat: funding and operational risks tied to global economic uncertainty and volatile credit markets impacting capital raises and collaborations. (AI summary of the Risk Factors section.)

What did OLMA report in its latest 8-K?

Olema Pharmaceuticals, Inc. (OLMA) filed an 8-K on November 12, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 5.03 (Amendments to Articles of Incorporation or Bylaws) and Item 8.01 (Other Events). Olema Oncology announced a corporate name change on November 12, 2026.

What are the latest OLMA SEC filings?

Olema Pharmaceuticals, Inc. (OLMA) filed its latest 10-K annual report on March 16, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on September 2, 2026.

What is OLMA's SEC CIK number?

Olema Pharmaceuticals, Inc. (OLMA)'s SEC Central Index Key (CIK) is 1750284. EDGAR lists every OLMA filing under that number.

Ask anything about OLMA

The research agent reads OLMA's filings, financials, insider trades and 13F holders, then answers with sources.